Bio-Sourcing

Bio-Sourcing, based in Belgium, produces biopharmaceuticals utilizing genetically modified goats' milk as a natural bioreactor.Bio-Sourcing specializes in biopharmaceutical production, established in 2014 in Liege, Belgium.Bio-Sourcing specializes in the production of biopharmaceuticals through a proprietary technological platform that harnesses the milk of genetically modified goats as a natural bioreactor. The core product offerings include fully human monoclonal antibodies and other biotherapeutics achieved via advanced gene-editing techniques such as CRISPR-Cas9 combined with nuclear transfer and reproductive technology. This innovative approach shifts biopharmaceutical production from traditional steel bioreactors to a more sustainable and efficient model, resulting in a significant reduction in production costs and carbon footprint. The primary end-users of these biopharmaceuticals are healthcare providers and institutions that require access to life-saving medications, particularly monoclonal antibodies.Bio-Sourcing's revenue model is primarily built around co-development and co-ownership of biopharmaceutical products with industry partners, enabling early income and long-term royalty revenues. The company engages in partnerships with governments and pharmaceutical firms, facilitating transactions that focus on producing large volumes of biopharmaceuticals while preserving or increasing gross margins for its clients. Such partnerships may involve direct agreements for the supply of bulk biopharmaceuticals or collaborative projects to develop new therapies. The pricing structure reflects the unique capabilities of their BioMilk Platform, supporting scalability and adaptability to market demands. Furthermore, Bio-Sourcing aims to penetrate new markets, particularly targeting regions with high demand for biotherapeutics by the end of 2026.

1. Series A

   Aug 6, 2014

   Amount

   $3.1M

   Investors

   Locked